appointment procedure, thus systematically compromising the legitimacy of a court composed of
the judges appointed in that way.
It was an inescapable conclusion that the continued operation of the NCJ as constituted by the 2017
Amending Act and its involvement in the judicial appointments procedure perpetuated the systemic
dysfunction established by the Court and might lead to further aggravation of the rule of law crisis in
Poland. Therefore, rapid action on the part of the Polish State to remedy this is required.
It falls upon the State of Poland to draw the necessary conclusions from this judgment and to take
appropriate measures in order to resolve the problems at the root of the violations found by the
Court and to prevent similar violations from taking place in the future.
Principal facts
The applicant, Advance Pharma sp. z o.o, is a limited liability company registered in Warsaw that
distributed a dietary supplement intended for men wishing to enhance their sexual performance.
The sale of that supplement was the sole source of income for the company, which in 2010
amounted to 20 million Polish zlotys (approximately 4.8 million euros).
In 2010 the product was withdrawn from the market following checks by the National
Pharmaceutical Institute in which some samples of the product were found to contain an active
molecule not allowed in dietary supplements and not listed on the product’s label. The applicant
company suspended its activities and appealed against the Main Pharmaceutical Inspector’s decision
to withdraw the product from the market. In the course of the appellate proceedings, the
administrative courts quashed that decision finding that the Inspector had failed to establish
whether the supplement had been a dietary supplement or a medicinal product and that the
decision had been given in breach of domestic law.
The applicant company, which in the meantime had destroyed its stocks of the supplement,
instituted a claim for damages in tort against the State in 2014. The courts notably found that the
applicant company had destroyed the supplement on its own initiative; the Inspector had only
ordered its withdrawal from the market. Moreover, the company had not proven that it had been
prevented from reintroducing the supplement once it had been made compliant with the relevant
regulations. The applicant company had therefore failed to prove the causal link between the
damages sought and the Inspector’s action.
After failing at two levels of jurisdiction, the applicant company lodged a cassation appeal with the
Supreme Court. The panel of three judges of the Civil Chamber of the Supreme Court, which
examined – and dismissed – the appeal, was entirely composed of judges newly appointed through
the procedure involving the new National Council of the Judiciary (NCJ) established in 2018.
Complaints, procedure and composition of the Court
Relying on Article 6 § 1 (right to a fair hearing), the applicant company complained that the
formation of the Civil Chamber of the Supreme Court, which had examined its appeal, had not been
a “tribunal established by law” because it was composed of judges recommended by the NCJ, a body
which had not offered any guarantees of independence or impartiality. It alleged that the entire
appointment procedure of the three judges that had heard its case had been neither transparent nor
independent and had not been subject to judicial review. It referred in particular to proceedings
before the Court of Justice of the European Union which ended in a ruling of 19 November 2019 and
rulings by the Polish Supreme Court and the Supreme Administrative Court finding that the judges of
the Supreme Court appointed in the procedure involving the NCJ were not a court constituted in
accordance with domestic law.
2